/* Custom styles used for all pages */
/* New Variables Section. Will try to make all colors changeable at top of this page, using the following variables, as well as a few other options. */

:root {
	--main-html-bg-color: white;					/* Change this to "background-color: transparent !important;" if using an image as the background */
	--main-body-bg-color: transparent;
	--main-content-bg-color: #FAFBFC;			/* This is currently the background color. It is on top of the html and the body elements, so takes precedence. */

	--main-font-color: black;
	--secondary-font-color: white;
	--main-title-color: #16539e;
	--main-title-shadow-color: #FFF;
	--main-subtitle-color: #16539e;

	--shadow-banner-color: #0c416700;			/* This is giving the banner a shaded look. The final 7th and 8th digits determine the opacity (alpha) of the over-layed color. */
/* 0c41674d */

	--main-button-bg-color: #0C4167;				/* Register buttons and Launch buttons */
	--button-font-color: white;
	--main-button-bg-color-hover: #081b33;
	--button-font-color-hover: white;
	--main-button-shadow-color: #305e7e80;

	--main-title-text-shadow-color: white;


	--footer-bg-color: #333333;

	--footer-main-link-color: #4A7090;
	--footer-second-link-color: #1675b9;
	--footer-main-link-hover-color: #041622;
	--footer-second-link-hover-color: #b6cedd;

	--presenter-name-color: #a32035;

	--player-footer-bg-color: #4e9add;				/* Changes the color of the social media bar on the player page */
	--player-footer-text-color: white;
	--player-footer-branding-link-color: #00536d;


	--show-banner: block;						/* Change this to "none;" if banner isn't needed */
	--show-header: none;						/* Change this to "block;" if header bar is needed */
}


/*********************************************** Top Level Section ***********************************************/
html {
	background-color: var(--main-html-bg-color);
}
body {
	background-color: var(--main-body-bg-color);
	color: var(--main-font-color);
	display: block;
	font-family: "Poppins",sans-serif;
	font-size: 14px;
	font-weight: 400;
	text-rendering: optimizeLegibility;
	-webkit-font-smoothing: antialiased;
	font-smoothing: antialiased;
	-moz-osx-font-smoothing: grayscale;
}
#ContentArea {
	display: flex;
	flex-direction: column;
	min-height: 100%;
	background-color: var(--main-content-bg-color);
	padding-top: 30px;
}
#container {
	background: unset;
	border: unset;
	width: unset;
	box-shadow: unset;
	-moz-box-shadow: unset;
	-webkit-box-shadow: unset;
	margin: 0 auto;
}
#branding {
	background-color: transparent;
	width: 100%;
	padding: 0;
	font-weight: bold;
	text-align: center;
	margin-top: auto;
	margin-bottom: 0;
}
/*********************************************** End Top Level Section ***********************************************/

/*********************************************** Banner Section ***********************************************/
#banner {
	display: var(--show-banner);
	border-radius: 30px;
	overflow: hidden;
	position: relative;
	margin-bottom: 48px;
}
#banner::before {
	content: "";
	width: 100%;
	height: 100%;
	position: absolute;
	top: 0;
	left: 0;
	background-color: var(--shadow-banner-color);
}
#banner > div {
	padding-right: 0;
	text-align: center;

}
#banner > img {
	max-height: unset;
	width: 100%;
	object-fit: cover;
	object-position: top;
}
/* Title stuff is in this section because titles are on top of banner in this template. */
.title {
	color: var(--main-title-color);
	text-align: center;
        font-weight: normal;
	position: absolute;
	top: 50%;
	left: 50%;
	-webkit-transform: translate(-50%, -50%);
	-o-transform: translate(-50%, -50%);
	transform: translate(-50%, -50%);
	text-shadow: 0px 0px 2px var(--main-title-shadow-color), 0px 0px 2px var(--main-title-shadow-color);
	width: 80%;
}
.title > h1 {
	font-weight: 500;
	font-size: calc(12px + 2vw);
	text-shadow: 
		1px 0 2px var(--main-title-text-shadow-color), 
		-1px 0 2px var(--main-title-text-shadow-color), 
		0 1px 2px var(--main-title-text-shadow-color), 
		0 -1px 2px var(--main-title-text-shadow-color), 
		0 0 3px var(--main-title-text-shadow-color), 
		0 0 5px var(--main-title-text-shadow-color);
}
.title > h1 > img {
	width: 245px;
}
.subtitle {
	color: var(--main-subtitle-color);
        font-weight: normal;
	margin-bottom: 40px;
}
/*********************************************** End Banner Section ***********************************************/

#header {
	display: var(--show-header);
	background-image: none;
	box-shadow: none;
}
#content p {
	padding: 0;
	margin-bottom: 1.3333rem;
}
.webcast_closed {
	    padding: 5px 15px;
}

/*********************************************** Footer Section ***********************************************/
#footer-container {
	padding: 0;
}
#footer {
	background-image: none;
	box-shadow: none;
	background-color: transparent;
	border: none;
}
#footer2 {
	background-image: none;
	box-shadow: none;
	background-color: var(--footer-bg-color);
	padding: 25px 0;
	border: none;
}
#footer2 {
	display: flex;
	-ms-flex-wrap: wrap;
	flex-wrap: wrap;
	justify-content: center;
}
#footer-right {
	width: 100%;
	font-size: 13px;
	color: #fff;
	font-weight: 400;
}
#footer-left {
	color: #333333;
	font-weight: 400;
	margin-bottom: 10px;
	width: 100%;
}
#footer a {
	color: #0C4167;
}
#footer2 a {
	color: #1675b9;
}
#footer a:hover {
	color: #041622;
}
#footer2 a:hover {
	color: #b6cedd;
}
.branding_name {
	margin-right: 3px;
}
.branding_name, .branding_date {
	display: inline-block;
}
@media screen and (max-width: 1091px) {
	#footer-right, #footer-left {
		float: none;
		text-align: center;
	}
}
@media screen and (max-width: 700px) {
	#branding {
		font-size: 2vw;
	}
}
/*********************************************** End Footer Section ***********************************************/

@font-face {
	font-family: 'Poppins';
	font-style: normal;
	font-weight: 400;
	src: local(''),
		url('https://www.meetview.com/resources/fonts/Poppins-Normal.ttf') format('truetype'),
		url('https://www.meetview.com/resources/fonts/Poppins-Normal.woff2') format('woff2');
}
@font-face {
	font-family: 'Poppins';
	font-style: normal;
	font-weight: 500;
	src: local(''),
		url('https://www.meetview.com/resources/fonts/Poppins-Medium.ttf') format('truetype'),
		url('https://www.meetview.com/resources/fonts/Poppins-Medium.woff2') format('woff2');
}
@font-face {
	font-family: 'Poppins';
	font-style: normal;
	font-weight: 700;
	src: local(''),
		url('https://www.meetview.com/resources/fonts/Poppins-Bold.ttf') format('truetype'),
		url('https://www.meetview.com/resources/fonts/Poppins-Bold.woff2') format('woff2');
}
#cover {
	position: fixed;
	height: 100%;
	width: 100%;
	top:0;
	left: 0;
	background: var(--main-content-bg-color);
	z-index: 9999;
}


/*********************************************** Custom Section ***********************************************/
#LogoTop {
	width: 100%;
	text-align: center;
	margin-bottom: 40px;
}
#LogoTop > img {
	width: 400px;
}
#LogoTopLeft {
	width: 250px;
	position: absolute;
	z-index: 1;
	display: none;
}
#tit1::before {
	content: "Early Age Onset Cancer Virtual Symposium";
	font-size: calc(12px + 2vw);
}
#sub1::before {
	content: "Barriers & Unequal Access to Timely Molecular Testing Results:";
	font-size: calc(12px + 1vw);;
	display: none;
}
#sub2::before {
	content: "Addressing the Inequities in Cancer Care Delays Across Canada";
	font-size: 30px;
	display: none;
}
#t1::before {
	content: "Click Here to Register Now!";
	font-size: calc(12px + 3vw);
	font-weight: bold;
	color: white;
	text-shadow: 1px 0 2px #0a2545, -1px 0 2px #0a2545, 0 1px 2px #0a2545, 0 -1px 2px #0a2545, 0 0 3px #0a2545, 0 0 5px #0a2545;
}
.title > h1 > span + br {
	display: none;
}
@media (max-width: 991px) {
	.container {
		max-width: 100%;
	}
}
.MainColor {
	color: #16539e;
}

.backButton {
	background-color: var(--main-button-bg-color);
	color: var(--button-font-color) !important;
	border-color: var(--main-button-bg-color);
	margin-top: 0;
	width: 100%;
	border-radius: 4px;
	padding: 12px 30px;
	border: none;
	background-image: none;
	font-weight: 500;
	font-family: inherit;
	font-size: 16px;
	line-height: 1.5;
	transition: color 0.15s ease-in-out,background-color 0.15s ease-in-out,border-color 0.15s ease-in-out,box-shadow 0.15s ease-in-out;
}
.backButton:hover {
	color: var(--button-font-color-hover) !important;
	background-color: var(--main-button-bg-color-hover);
	border-color: var(--main-button-bg-color-hover);
}
.backButton:focus {
	color: var(--button-font-color-hover) !important;
	background-color: var(--main-button-bg-color-hover);
	border-color: var(--main-button-bg-color-hover);
	box-shadow: 0 0 0 0.2rem var(--main-button-shadow-color);
}
/*********************************************** End Custom Section ***********************************************/

/* Custom styles for lobby page */
.enter_button {
	background-image: none;
	border-radius: 2px;
	box-shadow: none;
}
.broadcast-date {
	float: inherit;
	display: block;
}
.mini-cal {
	box-shadow: none;
	background-image: none;
}
.requirements {
	display: none;
}
.lobby_info {
	display: none;
}

@media (min-width: 1500px) {
	.container {
		max-width: 1440px;
	}
}
#cover {
	background-image: url("https://www.meetview.com/CCRAN20231026/images/loading-gif.gif");
	background-repeat: no-repeat;
	background-position: center;
}

/***** CUSTOM CCRAN *****/

.lobby_above {
	font-size: calc(12px + 0.4vw);
}

.ceo-wrapp {
	margin-top: 48px;
	margin-bottom: 0px;
}
.ceo-wrapp > p {
	font-size: 28px;
	padding-right: 40px;
	font-weight: bold;
	color: #000000;
}
.ceo-wrapp .ceo-detail {
	background-color: rgba(76,170,216,0.16);
	position: relative;
	padding: 24px 24px 24px 155px;
	margin-top: 30px;
}
.ceo-wrapp .ceo-detail .pict {
	width: 96px;
	height: 96px;
	border-radius: 100%;
	overflow: hidden;
	position: absolute;
	top: 24px;
	left: 24px;
}
.ceo-wrapp .ceo-detail h2 {
	font-size: 20px;
	font-weight: 700;
	margin-bottom: 0;
}
.ceo-wrapp .ceo-detail p {
	font-size: 14px;
}

#pills-tab, #pills-tab2 {
	display: flex;
	justify-content: space-around;
	font-size: calc(12px + 1vw);
}
table {
	background-color: white;
	text-align: left;
	/*max-width: 1000px;*/
	margin: 0 auto;
}
table > tbody > tr > td:nth-child(2) {
	text-align: left;
}
table > tbody > tr.darkRow {
	background-color: #98aee1;
}
table > tbody > tr.lightRow {
	background-color: #deeaf6;
}
table td {
	border: 1px solid black;
	padding: 5px;
	vertical-align: top;
}

#sponsorLogos > img {
	width: 200px;
	margin-bottom: 20px;
}
#sponsorLogos > img + img {
	margin-left: 18px;
}
#sponsorLogos > img.tier2 + img.tier2 {
	margin-left: 30px;
}
#sponsorLogos > img.tier1 {
	width: 500px;
}
#sponsorLogos > div.tier1 {
	font-weight: bold;
	font-size: 2rem;
}
#sponsorLogos > img.tier2 {
	width: 100%;
	max-width: calc(20% - 24px);
	max-height: 150px;
}
#sponsorLogos > div.tier2 {
	font-weight: bold;
	font-size: 2rem;
	/*margin-bottom: -10px;*/
}
#sponsorLogos > img.tier3 {
	width: 100%;
	max-width: calc(11% - 16px);
	max-height: 100px;
}
#sponsorLogos > div.tier3 {
	font-weight: bold;
	font-size: 2rem;
	margin-bottom: 20px;
}
#sponsorLogos > img.tier4 {
	width: 200px;
}
#sponsorLogos > div.tier4 {
	font-weight: bold;
	font-size: 2rem;
	margin-top: 20px;
	margin-bottom: -10px;
}
.sponsorImageWrapper {
	display: flex;
	flex-direction: row;
	justify-content: space-evenly;
	flex-wrap: wrap;
	align-items: center;
}

#TabImages {
	text-align: center;
	justify-content: center;
	font-weight: bold;
	margin-bottom: 30px;
}
#TabImages img {
	border-radius: 40px;
	height: 200px;
	border: 1px solid #4d8d98;
}


#myTab > li:nth-child(2) {
	/*display: none;*/
}
#pills-description-tab {
	display: none;
}
#pills-glossary-tab {
	/*display: none;*/
}
#banner, #LogoTopLeft, .accordion-toggle {
	cursor: pointer;
}
#pills-tab .nav-link.active {
	background-color: unset;
	color: #00536d;
}
table > tbody > tr > td:nth-child(2) > br + br , table > tbody > tr > td:nth-child(3) > br + br {
	content: "A";
	display: block;
	margin-bottom: 0.5em;
}
#regTitle {
	text-align: center;
	font-size: calc(14px + 1vw);
	font-weight: bold;
	margin-bottom: 40px;
	color: #16539e;
}
#regSubtitle {
	text-align: center;
	font-size: 28px;
	font-weight: bold;
	margin-bottom: 20px;
}
.break {
	color: #16539e;
}
.nameSponsor {
	font-size: calc(16px + 1vw);
}
table > tbody > tr > td:nth-child(1) > b, table > tbody > tr.accordion-toggle > td:nth-child(3) > b {
	/*font-weight: normal;*/
}
table > tbody > tr > td:nth-child(1) > b.timeTitle {
	font-weight: bold;
}
table > tbody > tr:nth-child(2) > td:nth-child(1) > b {
	font-weight: bold;
}
.ceo-detail > p:has(+ p) {
	margin-top: 5px !important;
	font-weight: bold;
}
.ccranSubtitle {
	font-weight: bold;
	font-size: 16px;
}
.glossaryWord {
	font-weight: bold;
	color: #16539e;
}


/*
#AparnaParikh:after {
	content: "Dr. Parikh is an expert in Gastrointestinal Cancers with a focus on Young Adults with Colorectal Cancer. ​Her clinical practice is comprised primarily of patients with colorectal cancer and pancreatic cancer. She ​is a member of the NCCN guidelines for Colorectal Cancer. She had a robust clinical trial portfolio with the hopes of bringing novel agents into the clinic, working closely with laboratory collaborators at MGH. She also leads the clinical liquid biopsy efforts for the GI Oncology group and is an international expert in liquid biopsies helping to develop these tools in the setting of residual disease after curative intent surgeries, to understand response to treatment as well as to understand drug resistance. Though she is a clinical translational researcher, she also has a passion and background in cancer care in low and middle-incomes countries and does work that supports access, equity and education in LMICs and as the Director of the Global Cancer Care Program at MGH.";
}
#ArminaLigaya:after {
	content: "Armina is a colorectal cancer survivor, who was first diagnosed while she was six months pregnant at a relatively young age. The whirlwind journey of becoming a mother was coupled with a fierce battle fighting this disease, one that included radiation, surgery and chemotherapy. She is extremely lucky to have caught this disease early. Thanks to her doctors, CCRAN, and the support of her husband, family and friends I am happy and healthy, and her daughter is thriving. She hopes to raise awareness of this disease to help others avoid going through the same ordeal.";
}
#AtoosaRashid:after {
	content: "With no prior health issues, no family history of cancer, and no known cancer genes, Atoosa Rashid was diagnosed with stage 2 colon cancer at the age of 26. After the discovery of the tumour in her sigmoid colon, she immediately underwent surgery, which was then followed by 12 rounds of aggressive chemotherapy. Now, three years post-treatment, she is engaged in various forms of cancer advocacy and fundraising. Recently, she became an Ambassador for Patient Care and Research through this year's Princess Margaret Home Lottery campaign. With early-onset colon cancer becoming an increasing issue, her goal is to continue raising awareness on the topic by sharing my personal cancer journey.";
}
#CassandraMacaulay:after {
	content: "Cassandra is the Senior Manager of Programs & Education at the Colorectal Cancer Resource & Action Network (CCRAN). She oversees CCRAN’s patient-focused and evidence-based portfolios serving the unmet needs of colorectal cancer patients and caregivers across Canada, and collaboratively leads CCRAN’s educational initiatives, both for patients and healthcare providers. Cassandra is a Medical Radiation Technologist with a graduate degree in health studies and leadership. She has worked in both patient-facing and project management roles and led the start-up of two nuclear medicine programs which improved access to diagnostic imaging in her community. She is passionate about health quality and improving the patient experience and is honoured to have the privilege of supporting, educating, and advocating for cancer patients and their caregivers.";
}
#CatherineMifsud:after {
	content: "Catherine is a 48 year old, married mother of 3 young adult children. Catherine is currently in the middle of her career as a Sr Supervisor for Patient Services at a Global Medical Technology company where she has worked for almost 20 years. Catherine was diagnosed with cancer in the sigmoid junction in January 2023. After pushing for a second opinion from the Young Colorectal Cancer Clinic at Sunnybrook, she was re-diagnosed with rectal cancer. Catherine had short course radiation and then proceeded to have a low anterior resection surgery on May 3, 2023. Catherine's final pathology determined that she had Stage II rectal cancer and no chemo was required. She has almost been NED for 6 months . Catherine is passionate about patient advocacy and sharing her story in hopes to help others navigate and advocate for themselves as they go through their own cancer journey. She has recently been certified as CCRAN's Early stage cancer coach through our Cancer Coach support program.";
}
#DawnRichards:after {
	content: "Dawn Richards, PhD, is the founder of Five02 Labs Inc., and Director of Patient and Public Engagement at Clinical Trials Ontario. With a PhD (Analytical Chemistry) from the University of Alberta, and experience in a variety of roles during the past 20 years, it is her diagnosis with rheumatoid arthritis 15 years ago that started her journey to combine her passion for science with making the most of her diagnosis. In her role at CTO, Dawn is charged with executing on CTO's strategic pillar of patient and public engagement.";
}
#EminaEmiliaTorlakovic:after {
	content: "Dr. Emina Emilia Torlakovic obtained her M.D. at the University of Zagreb Medical School and her Ph.D. at the University of Oslo Medical School. She is board certified by The American Board of Pathology in Anatomic and Clinical Pathology with subspecialty boards in Hematopathology. She is a professor at the Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, with previous appointment at the University of Toronto. She is a Division Head of Hematopathology, Saskatchewan Health Authority. She was a founding member of the NordiQC, has co-founded CIQC, and most recently founded Canadian Biomarker Quality Assurance (CBQA) as well as CBQAReadout.ca (inter)national academic quality assurance programs, which she is currently directing. Dr. Torlakovic is the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. She is the President of the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and a Board Member of the International Quality Network for Pathology (IQN Path). She is also currently leading several projects related to national and global standardization of clinical IHC applications.";
}
#EricChen:after {
	content: "Dr. Eric Chen is a medical oncologist at Princess Margaret Cancer Center and an associate professor at Faculty of Medicine, University of Toronto. He specializes in treating gastrointestinal malignancies, mainly colorectal cancer, hepatocellular carcinoma and gastroesophageal cancers. His research focuses on the development of new treatments for patients with these conditions. He currently participates in many clinical trials, including targeted therapy and immunotherapy in colorectal cancer. He is also a valued member of CCRAN’s medical and scientific advisory board and a clinician champion for access to clinical trials.";
}
#FeliciaNewell:after {
	content: "Felicia Newell is CCRAN's National Registered Dietitian. She has a Bachelor and Masters of Science in Applied Human Nutrition, and has worked in areas such as research, education, healthcare, and private practice for 14 years. She is has an immense passion for providing help and guidance to all patients, but especially those fighting colorectal cancer. Felicia assesses patients for their nutritional needs and provides evidenced-informed nutrition recommendations and support to help optimize their bodies’ ability to fight cancer and tolerate treatments. She also oversees the expansion of CCRAN's My Foods for Life Program, in addition to the development of a primary and secondary cancer prevention program.";
}
#GonzaloSapisochin:after {
	content: "Dr. Gonzalo Sapisochin is Staff Surgeon at The Toronto General Hospital, UHN. Dr. Sapisochin received his Medical Diploma in 2005 from the Universidad Complutense de Madrid, Spain and went on to complete his General Surgery residency training in 2011 at the University Hospital of Vall d’Hebron in Barcelona where he successfully defended his Doctoral Thesis, “Optimization of Liver Transplantation for Hepatocellular Carcinoma”, to receive his PhD be the Universidad Autonoma de Barcelona. He went on to complete his Clinical Fellowship in Abdominal Transplant & HPB Surgical Oncology with the University of Toronto and was subsequently recruited in a position at the Toronto General Hospital as Staff Surgeon with the Multi-Organ Transplant Program and the Division of General Surgery. He is currently an Associate Professor of Surgery at the University of Toronto. Dr. Sapisochin main research interest is the “interface” between liver transplantation and cancer. He has been one of the drivers of the concept of Transplant Oncology and chaired in 2019 the ILTS Consensus Conference in this topic. He has focused his research in the management of hepatocellular carcinoma, cholangiocarcinoma and colorectal liver metastases. He has published more than 150 original manuscripts in peer-reviewed journals such as Journal of Hepatology and Annals of Surgical Oncology.";
}
#JessicaDasler:after {
	content: "Jessica lives in North Vancouver, BC with her husband and 5 year old daughter. She loves being in nature and being as healthy/active as she can be. She loves to garden as this is her therapy. Her little family is her motivation and her diagnosis is her full time job. Prior to her stage IV colorectal cancer diagnosis in January 2021, she worked in the school system as a resource for children with special needs. She continues to be an advocate for others navigating the medical system as she has faced many challenges. Her zest for life has allowed her to take a terrible situation and turn it into an empowering educational experience.";
}
#JimPalma:after {
	content: "Jim Palma is Executive Director of TargetCancer Foundation. Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, he spent eleven years at Fidelity Investments in Boston, MA. Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD), and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the GI Cancers Alliance and the Global Cholangiocarcinoma Alliance. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.";
}
#JoannaKirsh:after {
	content: "Joanna is 33 years old and was diagnosed in 2022 with stage 1B cervical cancer. She underwent two surgeries, as well as radiation, for her treatment and is now under observation for the next 4 years. She's getting back to enjoying her hobbies of dance, live music, reading and travelling, as well as participating in a monthly AYA committee as a patient representative and being an active member in the AYA community.";
}
#JosePerea:after {
	content: "Dr. Jose Perea is an MD and PhD, with specialties of General and Digestive surgery and with special interest in surgical oncology. He has developed three clearly defined and interrelated aspects during more than 15 years, focusing my research specifically on Early-onset colorectal cancer. He has been a surgeon in the Colorectal Surgery Unit at the 12 de Octubre University Hospital for 10 years, and later at the Jiménez Díaz Foundation University Hospital. In both institutions he has been Principal Investigator in the Research Institute. He has also been Adjunct Professor of Surgery for 9 years of the Medicine School of the Complutense University, in Madrid. In addition to being a member of different committees within the Department (Research, Teaching, and Postgraduate) He is currently applying for accreditation for University Full Professor. He has coordinated seven PhD students, and currently another 5. He is now Chief of the Department of Surgery at Vithas Arturo Soria University Hospital, where he is also Professor of Surgery for the European University of Madrid. He is also the Principal Investigator at the Institute of Biomedical Research of Salamanca. His research interests cover different aspects of Colorectal cancer (CRC), especially in early-onset (as previously mentioned) and multiple primary CRC forms, apart from hereditary syndromes. In recent years he has been developing a network of collaboration between different centers in Spain (Spanish Early-onset Colorectal cancer consortium, SECOC), and is now also developing a worldwide collaboration for the study of this subtype of CRC (GEOCODE: Global EOCRC Database). This dedication to the Early-onset CRC has led to be an international reference on this field, having participated in different initiatives focused on fixing the theoretical lines of future research of this subtype of CRC. He chaired and coordinated the Annual Early-onset CRC International Symposium, in Madrid, which has been held annually from 2020 in collaboration with Fight Colorectal Cancer.";
}
#LauraPalma:after {
	content: "Laura received her Master of Science degree in Genetic Counselling from the University of Toronto in 2005 and joined the Division of Medical Genetics at the McGill University Health Center in Montreal, Quebec, where she remains today. She is certified by both the American Board of Genetic Counselors and the Canadian Association of Genetic Counsellors. With over 18 years of clinical experience, Laura provides genetic counselling to patients and families at risk for a variety of hereditary cancer and neoplasia syndromes, both in the adult and pediatric settings. She is an Assistant Professor in the McGill Department of Human Genetics and is actively involved in teaching, clinical research, and supervision of genetic counselling students. Laura has contributed to the development and implementation of mainstreaming genetic testing initiatives for both breast and ovarian cancer at her hospital institution. She was also the PI on the MUSE study (Mismatch Repair Universal Screening for Endometrial cancer) which is the only study in Quebec to examine rates of Lynch syndrome amongst universally screened endometrial cancers. Her research interests are in the areas of hereditary cancer, biomedical ethics, and alternative models of genetic service delivery to improve access to cancer genetic testing.";
}
#LindsayHlushak:after {
	content: "Lindsay is 35-year-old and living with lung cancer. She was diagnosed near the end of 2019 at the age of 31, she was an avid runner, relatively healthy otherwise, and was diagnosed because my GP thought she should send her for a chest x-ray to confirm she didn't have pneumonia after seeing her for a persistent cold. After her first round of treatments wrapped up in 2021, She was followed for routine scans to watch her tumor and make sure it didn't start growing. In the summer of 2023, an abnormal scan landed her on treatment again, however, this time it will be a lifelong treatment, complete with random side effects to monitor. She has an amazing support group with her friends and family who keep her going every day. She also spends her time exploring outdoors either through off-roading (a newer hobby for her) or hiking/boarding in the mountains. She has two dogs that are her absolute joy in life, and she spend lots of time with them on walks or in the dog park.";
}
#MarceloCypel:after {
	content: "Dr. Cypel is a Staff Thoracic Surgeon at University Health Network (UHN) and a Professor of Surgery at the University of Toronto. He is the Surgical Director of the Ajmera Transplant Center at UHN and Artificial Lung Program at UHN. He received his MD in 1999 and completed his general surgery and thoracic surgery residency program in 2004. In 2005 he started his post-doctoral research fellowship at the Latner Thoracic Surgery Laboratory. During this time, he developed a new method of lung preservation and donor lung repair called Ex Vivo Lung Perfusion (EVLP). This method is now used clinically in Toronto and in many other centers, and has significantly increased the number of transplantable lungs. He subsequently performed a 3 years fellowship in thoracic oncology, cardiac surgery, and lung transplantation at the University of Toronto. Dr. Cypel has a large number of 1st and senior author peer review publications including high impact journals such as Science Translational Medicine, The New England Journal of Medicine and The Lancet. His main clinical interests are in artificial lung devices, Ex vivo and In vivo Lung Perfusion and lung transplantation. Dr. Cypel currently holds the prestigious Canada Research Chair in Lung Transplantation from the Government of Canada and he is the principal investigator in very innovative clinical trials, such as the use of uncontrolled donation after cardio-circulatory death for lung transplantation and in vivo lung perfusion with chemotherapy to treat patients with lung metastases. He is a Member of the American Association for Thoracic Surgery (AATS) and a Fellow from the Royal College of Physicians and Surgeons of Canada (FRCSC).";
}
#MarlieSmith:after {
	content: "Marlie has held the role as clinical nurse specialist with the Adolescent and Young Adult Program at the Princess Margaret Cancer Centre since November 2021. Prior to graduating from the University of Toronto with her Master of Nursing, Marlie worked in the outpatient haematology/oncology clinic at The Hospital for Sick Children since 2016. Marlie is passionate about providing psychosocial support to young patients navigating a cancer diagnosis, and often refers to herself as a "cancer cheerleader" to empower her patients to live well and to continue working toward life milestones while undergoing treatment. Apart from work, Marlie enjoys backcountry camping, going for bike rides, playing beach volleyball and spending time by the water.";
}
#MicheleWright:after {
	content: "Michele Wright is the Coordinator, Patient Care Initiatives at Lung Cancer Canada. After obtaining her degree in Developmental Psychology and Sociology at the University of Toronto, Michele has worked in health care supporting patients for over 20 years. Her previous roles include Patient Care Coordinator for Heart and Lung Transplant at SickKids Hospital in Toronto. She values a person-centered approach and seeks to empower patients to take a partnership role with their health care providers. During the pandemic, she moved to rural Tottenham, ON, with her husband and bulldog, where they make maple syrup and raise bees.";
}
#MonikaSlovinecDAngelo:after {
	content: "Monika Slovinec D’Angelo, PhD is a health scientist with broad experience in population health and healthcare transformation. She specializes in health promotion, chronic disease prevention and optimized management, with expertise in intervention and implementation research, program development and evaluation, stakeholder engagement, and strategic capacity building at organizational and system levels. She has worked across healthcare delivery, health research, and academic organizations, and in consultancy roles, collaborating with health system stakeholders nationally and internationally to develop and deploy evidence-based solutions in support of innovative initiatives and sustainable programs and systems. She is a firm believer of health in all policies and applies systems thinking to problem solving. Her passion lies in co-creating strategic solutions to promote health and wellbeing across populations.";
}
#NancyNixon:after {
	content: "Dr. Nancy Nixon is a full time medical oncologist at the Tom Baker Cancer Centre and Assistant Professor at the University of Calgary.  She specializes in the treatment of breast cancer, and is the Southern Alberta Tumour Team Lead for medical oncology.";
}
#PaulJKaranicolas:after {
	content: "Dr. Karanicolas received his MD degree from the University of Western Ontario in 2003 & his PhD in health research methodology, clinical epidemiology and bio statistics from McMaster University in 2008. He completed his residency in general surgery at Western University in 2009 and a fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Centre in 2011. Dr. Karanicolas is a surgical oncologist & scientist at the Odette Cancer Centre at Sunnybrook Health Sciences Centre & holds a Professor title at both the Department of Surgery and the Institute of Health Policy, Management & Evaluation at the University of Toronto. The overarching theme of his research program is the development & conduct of clinical trials in surgical oncology. Dr. Karanicolas is also the surgical lead for the hepatic artery infusion pump chemotherapy program at the Odette Cancer Centre, the only such program in Canada.";
}
#RaviRamjeesingh:after {
	content: "Dr. Ramjeesingh joined the Division of Medical Oncology at Dalhousie University in May 2015 as a staff physician and promotion to Associate Professor in 2020. He completed his Ph.D in cancer research in 2004, and his doctor of medicine in 2008 at the University of Toronto. He then subsequently completed his Internal Medicine and Medical Oncology residencies at Queen’s University before completed a clinical trials methodology fellowship at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario. His main clinical expertise is in the areas of hepatopancreobiliary (HPB) cancers and breast cancer. He is currently the chair of the HPB Disease site group in Nova Scotia and is the Medical Director of AACRU, the Nova Scotian oncology clinical trials group. Nationally, he is a founding member of the Canadian GI Oncology Evidence Network and is a board member of Craig’s Cause Pancreatic cancer society. His research activities are in the fields of health service delivery, and translational research in oncology.";
}
#RobRutledge:after {
	content: "Dr. Rob Rutledge, MD, FRCPC has been a full-time Radiation Oncologist for over 27 years treating breast, prostate and pediatric cancers, and is an Associate Professor at Dalhousie University in Halifax, Nova Scotia. His passion is empowering people with science and wisdom-based healthy lifestyle habits and healing techniques. He has organized and delivered hundreds of free public talks and day-long seminars, and over 60 weekend retreats in 30 cities attended by 2000+ participants. He is the co-founder of CancerPEP.org, a comprehensive home-based six-month daily Patient Empowerment Program proven to improve the mental and physical health of people on the cancer journey.";
}
#SafiyaKarim:after {
	content: "Safiya Karim is a medical oncologist and Clinical Associate Professor at the Tom Baker Cancer Centre and the University of Calgary.  She completed her medical school at the University of Calgary in 2011 and subsequently completed her medical oncology residency at the University of Toronto in 2016. She completed a fellowship in health services research at Queen’s university as well as a Master’s degree in health care quality and patient safety. She serves as the director of the Medical Oncology Fellowship Program and Assistant Director of the Oncology Outcomes (02) program.  She is also the co-chair of the Choosing Wisely Canada Oncology working group. Her clinical practice is in gastrointestinal and genitourinary cancers. Her research interests include real world evidence and outcomes, quality improvement, and global oncology. In her spare time, she enjoys running, biking and yoga.";
}
#ShujiOgino:after {
	content: "Dr. Ogino has spearheaded to develop the integrative scientific field of molecular pathological epidemiology (MPE).  Dr. Ogino founded the International Molecular Pathological Epidemiology (MPE) Meeting Series (www.mpemeeting.org) in 2013 and has been serving as its Chair/Co-Chair for six past meetings.  Leveraging the MPE approach, Dr. Ogino is a leading investigator to study the interactive roles of exposures, genetics, systemic conditions such as obesity, microbiome, and immunity in cancer biology and etiologies.  He has conducted multimodal, multi-omic studies using large-scale prospective cohort studies and clinical trials, having discovered the etiological links between certain diets / lifestyle factors and microbiota / immune cell infiltrates in the tumor microenvironment.  Recently, Dr. Ogino devotes his research effort to early-onset cancers that have shown increased incidence.";
}
#StephanieCondon:after {
	content: "Stefanie Condon-Oldreive has been an elementary school teacher for the past 20 years. Additionally, she is Founder/Director of Craig's Cause Pancreatic Cancer Society (CCPCS), over seeing all four pillars of the organization: Public Awareness, Patient Support, Healthcare Education and Research and operation of the society. Additionally, Stefanie is proud of CCPCS's creation of the National Pancreas Conference, Canada's only accrediated disease specific conference for pancreatic cancer and the World's first PERT Calculator that was approved through Health Canada and used by both pancreatic cancer and cyctic fibrosis communities. Stefanie is proud to partner with CCRAN and be part of their important work.";
}
#SteveSlack:after {
	content: "Steve is married with two teenage sons. In 2021, At age 48, after 2 years of symptoms, his family doctor finally referred him for a colonscopy which uncovered a large tumour in the sigmoid section of his colon. A few days later, an MRI scan confirmed 23 metastatic lesions on his liver as well. He underwent emergency colon resection surgery, and after recovering from that he began systemic therapy with FOLFIRI and Panitumumab. Six months into that, he had surgery to implant a Hepatic Artery Infusion Pump and then did 6 rounds of HAIP chemo infusions in conjunction with continued systemic therapy. He now has only one lesion remaining on his liver, and he has been accepted into the Living Donor Liver Transplant program at Toronto General Hospital. He is hoping to have liver transplant surgery in late 2023.";
}
#TeresaHolmes:after {
	content: "Teresa lost a beloved sister to cholangiocarcinoma in 2021. Together with other motivated Canadians, Teresa and her family are starting up a new charity in Canada, called Cholangio-Hepatocellular Carcinoma Canada. The goal of this new charity is to extend and improve the quality of life of those affected by cholangiocarcinoma and hepatocellular carcinoma by raising awareness, providing information resources, and building patient support networks.";
}
*/


#day1Table > tbody > tr > td:nth-child(3) {
	/*display: none;*/
}
#day1Table > tbody > tr > td:nth-child(2) b {
	/*font-weight: normal;*/
}
#day1Table .accordian-body {
	display: none;
}
#day1Table .accordion-toggle {
	cursor: unset;
}
#day2Table > tbody > tr > td:nth-child(3) {
	/*display: none;*/
}
#day2Table > tbody > tr > td:nth-child(2) b {
	/*font-weight: normal;*/
}
#day2Table .accordian-body {
	display: none;
}
#day2Table .accordion-toggle {
	cursor: unset;
}
#ResourceSection {
	display: none;
}


/*recreated - not from cache - process time 0.015229940414429 */